# Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk

> **NCT05487950** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 550 (estimated)

## Conditions studied

- Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)

## Interventions

- **DRUG:** Rivaroxaban group

## Key facts

- **NCT ID:** NCT05487950
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-04-05
- **Primary completion:** 2027-04-05
- **Final completion:** 2027-04-05
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05487950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05487950, "Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05487950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*